Affiliation:
1. Catherine N Verme-Gibboney PharmD, Senior Medical Information Specialist, GlaxoSmithKline, Philadelphia, PA
2. Marcie J Hursting PhD, Director, Clinical Science Consulting, Potomac, MD
Abstract
OBJECTIVE: To retrospectively evaluate clinical experiences with argatroban dosing, particularly incremental dosage adjustments, during a clinical trial of argatroban anticoagulation in heparin-induced thrombocytopenia (HIT). METHODS: Records of 304 patients with HIT administered argatroban during a prospective study were reviewed to determine each dose, incremental dosage adjustment, and duration of therapy. Dosing information (stratified by patient initial dose) and incremental adjustments (overall, and stratified by dose from which adjustment occurred) were summarized. The relationship between median incremental adjustments and adverse outcomes, including bleeding, was investigated. RESULTS: Two hundred seventy-one (89%) patients received initial doses of 1.9–2.1 μg/kg/min (group B). Twenty-six (9%) patients were started at a lower dose. Group B's median (5–95th percentile) final dose was 1.6 (0.25–4.0) μg/kg/min. During a median of 6 days of argatroban therapy, patients underwent a median of 3.0 dosage adjustments using a median and mode incremental adjustment of 0.5 μg/kg/min (5–95th percentile, 0.1–2.0 μg/kg/min). Fifty-two (17%) patients required no dosage adjustment. Incremental adjustments decreased with decreasing current dose (e.g., median 0.25 μg/kg/min from doses of 0.26–0.75 μg/kg/min). Outcomes were similar between patients with no adjustment or with median incremental adjustments of ≤0.4, 0.41–0.75, or >0.75 μg/kg/min. CONCLUSIONS: Based on this clinical experience, together with the established linear pharmacokinetics and pharmacodynamics of argatroban, appropriate dosage increments may be proposed for argatroban-treated patients with HIT. Incremental adjustments of 0.5 μg/kg/min are reasonable for most patients. Smaller adjustments (e.g., 0.25 μg/kg/min) should be used when modifying lower doses, such as those recommended for use in hepatically impaired patients.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparison of percent adjusted versus predefined incremental argatroban dosing nomograms in patients with heparin induced thrombocytopenia;Thrombosis Update;2021-08
2. Argatroban☆;Reference Module in Biomedical Sciences;2016
3. Argatroban;Meyler's Side Effects of Drugs;2016
4. Thrombin inhibitors, direct;Meyler's Side Effects of Drugs;2016
5. Comment;Annals of Pharmacotherapy;2015-03-11